A5048343406- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Ocular Oncology and Treatments
- Brain Metastases and Treatment
- Computational Drug Discovery Methods
- Biosimilars and Bioanalytical Methods
- Cancer Genomics and Diagnostics
- Immune cells in cancer
- Multiple Myeloma Research and Treatments
- Nanoplatforms for cancer theranostics
- Cancer Cells and Metastasis
- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Treatments and Studies
- Antenna Design and Analysis
- Inflammatory Biomarkers in Disease Prognosis
- Nonmelanoma Skin Cancer Studies
- Polyomavirus and related diseases
- Esophageal and GI Pathology
- Full-Duplex Wireless Communications
- Cell Image Analysis Techniques
- Retinal Development and Disorders
Istituto Oncologico Veneto
2015-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2014-2024
Royal Australasian College of Surgeons
2017
The University of Adelaide
2017
New York University Press
2017
Cambridge University Press
2017
Regione del Veneto
2014
Ospedale Santa Chiara
2005
Clinical responses to ipilimumab are variable in terms of onset, magnitude and duration. Upfront identification patients who more likely or unlikely benefit from treatment is a major need.Prospectively collected data 720 advanced melanoma treated with 3 mg/kg within the Italian expanded access program were analyzed. The derived neutrophil-to-lymphocyte ratio (dNLR) was calculated baseline peripheral blood cell counts, receiver operating characteristic curve used evaluate best cutoff for this...
PURPOSE Nivolumab 1 mg/kg plus ipilimumab 3 (NIVO1+IPI3) is approved for first-line treatment of patients with advanced melanoma in several countries. We conducted a phase IIIb/IV study (CheckMate 511) to determine if nivolumab (NIVO3+IPI1) improves the safety profile combination. PATIENTS AND METHODS Patients (N = 360) age 18 years or older previously untreated, unresectable stage III IV were randomly assigned 1:1 NIVO3+IPI1 NIVO1+IPI3 once every weeks four doses. After 6 weeks, all...
Ipilimumab and nivolumab have each shown treatment benefit for high-risk resected melanoma. The phase III CheckMate 915 trial evaluated adjuvant plus ipilimumab versus alone in patients with stage IIIB-D or IV melanoma.In this randomized, double-blind, trial, 1,833 received 240 mg once every 2 weeks 1 mg/kg 6 (916 patients) 480 4 (917 ≤ year. After random assignment, were stratified by tumor programmed death ligand (PD-L1) expression stage. Dual primary end points recurrence-free survival...
Ipilimumab improves survival in patients with advanced melanoma. The activity and safety of ipilimumab outside a clinical trial was assessed an expanded access programme (EAP). available upon physician request for aged 16 or over pretreated stage III (unresectable)/IV melanoma, whom no other therapeutic option available. Patients received 3 mg/kg every weeks four doses. stable disease objective response to were eligible retreatment progression. Tumour assessments conducted at baseline week...
Ipilimumab is a licensed immunotherapy for metastatic melanoma patients and, in the US, as adjuvant treatment high risk radically resected. The use of ipilimumab associated with typical but unpredictable pattern side effects. purpose this study was to identify clinical features and blood biomarkers capable predicting related toxicity.We performed prospective aimed at analyzing potential biological markers immune-related toxicity treated (3 mg/kg, q3w). We enrolled 140 consecutive disease....
Abstract Patients with melanoma brain metastases have a poor prognosis and historically been excluded from clinical trials. The Expanded Access Program (EAP) provided an opportunity to evaluate the feasibility of ipilimumab (3 mg/kg every 3 weeks for four doses) in patients stage (unresectable) or 4 asymptomatic metastases, who had failed did not tolerate previous treatments no other therapeutic option available. Tumor assessments were conducted at baseline week 12 using immune-related...
Elderly patients with metastatic melanoma have different disease characteristics and a poorer prognosis than younger patients. Data from clinical trials expanded access programmes (EAPs) suggest ipilimumab confers consistent survival benefit has similar safety profile across age groups of melanoma. Here we report the efficacy 3 mg/kg in elderly enrolled an EAP Italy. Patients aged > 70 years pretreated received every weeks for four doses through EAP. Tumour response was evaluated at baseline...
Background Obesity is a risk factor for malignancy; however, its prognostic role in patients with metastatic melanoma controversial. We aim to investigate the of body mass index (BMI) receiving mitogen-activated pathway kinase inhibitors (MAPKi), immune checkpoint (ICIs) alone or their sequence. Methods Data on ≥1 line systemic treatment were retrieved from prospectively collected databases. Progression-free survival (PFS) and overall (OS) analyzed by means multivariable stratified Cox...
Abstract Melanoma heterogeneity is a hurdle in metastatic disease management. Although the advent of targeted therapy has significantly improved patient outcomes, occurrence resistance makes monitoring tumor genetic landscape mandatory. Liquid biopsy could represent an important biomarker for real-time tracing evolution. Thus, we aimed to correlate liquid dynamics with treatment response and progression by devising multiplatform approach applied longitudinal melanoma monitoring. We conceived...
Ipilimumab, the first immune-checkpoint inhibitor extending overall survival (OS) in metastatic melanoma patients, has a benefit only proportion of patients and development reliable predictive biomarkers is still an unmet need. To meet this request, we used multivariate statistical approach to test whether myeloid-derived suppressor cells (MDSC) or other tumor-associated immunological parameters may serve as prognostic receiving ipilimumab. By using standardized determine circulating levels...
Abstract Background: NIVO has demonstrated significant benefit over IPI as adjuvant treatment in pts with resected stage IIIB–C or IV melanoma (AJCC v7). Combination + shown numerically longer survival than alone metastatic melanoma. CheckMate 915 evaluated 1 mg/kg Q6W vs NIVO. Methods: Pts aged ≥ 12 y completely IIIB–D v8) were stratified by tumor PD-L1 expression and treated 240 mg Q2W (NIVO IPI1) placebo-controlled 480 Q4W for ≤ to be discontinued together). Dual endpoints recurrence-free...
Abstract Background To evaluate the capability of basal and one-month differed white blood cells (WBC), neutrophil, lymphocyte platelet values their ratios (neutrophils-to-lymphocytes ratio, NLR, platelets-to-lymphocytes PLR) in predicting response to i mmune checkpoint inhibitors (ICI) metastatic melanoma (MM). Methods We performed a retrospective study 272 BRAF wild-type MM patients treated with first line ICI. Bivariable analysis was used correlate patient/tumor characteristics clinical...
Abstract Background Immune Checkpoint Inhibitors (ICIs) lead to durable response and a significant increase in long-term survival patients with advanced malignant melanoma (MM) Non-Small Cell Lung Cancer (NSCLC). The identification of serum cytokines that can predict their activity efficacy, sex interaction, could improve treatment personalization. Methods In this prospective study, we enrolled immunotherapy-naïve affected by MM NSCLC treated ICIs. primary endpoint was dissect the potential...
Background Immune checkpoint inhibitors (ICIs), namely, anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody Ipilimumab and anti- programmed cell death 1 (PD-1) antibodies Nivolumab, Pembrolizumab, have improved the treatment outcomes for many other cancer types. However, their impact on fertility remains under-explored. Methods The possible direct effects of ICIs human sperm was investigated. Spermatozoa from ten normozoospermic donors were exposed to Ipilimumab, or...
This study compared the central nervous system (CNS) metastasis incidence between a temozolomide- and dacarbazine-based regimen in untreated stage IV melanoma patients. A total of 150 patients were randomly assigned to receive either oral temozolomide (200 mg m−2 per day; days 1–5) or intravenous dacarbazine (800 m−2; day 1), combination with cisplatin (75 1) subcutaneous interleukin-2 (3 MU twice daily; 9–18), every 28 (CTI CDI). 149 eligible for an intention-to-treat analysis (CTI: n=74,...
Uveal melanoma (UM) represents the most common primary intra-ocular malignancy in adults. Up to 50% of patients develop distant metastases within 10 years from diagnosis, with liver as site. Upon metastatization, life expectancy strongly reduces and immune checkpoint inhibitors that prove effective cutaneous do not modify clinical outcome. To date, few studies have focused on deciphering immunomodulatory features metastatic UM microenvironment, there are no prognostic models for use. This...